Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Meet Our Editorial Board Member
Volume: 18 Issue: 2
Author(s): Dayong Wu
Affiliation:
Export Options
About this article
Cite this article as:
Wu Dayong , Meet Our Editorial Board Member, Endocrine, Metabolic & Immune Disorders - Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/187153031802180213144320
DOI https://dx.doi.org/10.2174/187153031802180213144320 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
17
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Insight into Early Diagnosis of Multiple Sclerosis by Targeting Prognostic Biomarkers
Current Pharmaceutical Design Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets COVID-19: Potassium Contributes to Pathologies that Cause Disability
Infectious Disorders - Drug Targets Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders
Current Neuropharmacology Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening The Pro-Apoptotic Substance Thapsigargin Selectively Stimulates Re-Growth of Brain Capillaries
Current Neurovascular Research Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents ADAMTS Proteinases: Potential Therapeutic Targets?
Current Pharmaceutical Biotechnology Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Programmed Symptoms: Disparate Effects United by Purpose
Current Rheumatology Reviews Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy
Current Bioactive Compounds P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets